Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20261089 | 1.00 | KMT2A (0.35) | KMT2ATHRBMEN1ACHEEPHX1 | |
| SCHEMBL20983759 | 1.00 | KMT2A (0.35) | KMT2ATHRBMEN1ACHEEPHX1 | |
| SCHEMBL24959762 | 1.00 | KMT2A (0.35) | KMT2ATHRBMEN1ACHEEPHX1 | |
| SCHEMBL20836937 | 1.00 | KMT2A (0.35) | KMT2ATHRBMEN1ACHEEPHX1 | |
| SCHEMBL18616072 | 0.97 | KMT2A (0.37) | KMT2ATHRBMEN1ACHEEPHX1 | |
| SCHEMBL21771088 | 0.97 | KMT2A (0.37) | KMT2ATHRBMEN1ACHEEPHX1 | |
| SCHEMBL19301943 | 0.97 | KMT2A (0.37) | KMT2ATHRBMEN1ACHEEPHX1 | |
| Cyclohexylamine SCHEMBL23883677 | 0.97 | KMT2A (0.37) | KMT2ATHRBMEN1ACHEEPHX1 | |
| SCHEMBL19391996 | 0.97 | THRB (0.37) | KMT2ATHRBMEN1ACHE | |
| SCHEMBL6906552 | 0.97 | KMT2A (0.37) | KMT2ATHRBMEN1ACHEEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019110663-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2019-06-13 | — | — | WO | disclosed |